FDA Approves Olutasidenib for Acute Myeloid Leukemia Subtype
FDA approved olutasidenib for relapsed/refractory AML with IDH1 mutation, alongside Abbott RealTime IDH1 Assay for patient selection. Study 2102-HEM-101 showed 35% CR+CRh rate, median CR+CRh duration of 25.9 months, and significant transfusion independence. Common adverse effects included nausea, fatigue, and arthralgia.
Related Clinical Trials
Reference News
FDA Approves Olutasidenib for Acute Myeloid Leukemia Subtype
FDA approved olutasidenib for relapsed/refractory AML with IDH1 mutation, alongside Abbott RealTime IDH1 Assay for patient selection. Study 2102-HEM-101 showed 35% CR+CRh rate, median CR+CRh duration of 25.9 months, and significant transfusion independence. Common adverse effects included nausea, fatigue, and arthralgia.